首页> 外文期刊>Saudi Journal of Anaesthesia >Dexmedetomidine for monitored anesthesia care in patients undergoing liberation procedure for multiple sclerosis: An observational study
【24h】

Dexmedetomidine for monitored anesthesia care in patients undergoing liberation procedure for multiple sclerosis: An observational study

机译:右美托咪定用于接受解放性多发性硬化手术患者的麻醉监测:一项观察性研究

获取原文
       

摘要

Background: It has been postulated that Multiple sclerosis (MS) stems from a narrowing in the veins that drain blood from the brain, known medically as chronic cerebrospinal venous insufficiency, or CCSVI. It has been proposed that balloon angioplasty should alleviate the symptoms of MS. This procedure is also known as The “Liberation Procedure”. Accordingly, a clinical study was undertaken to determine the effects of dexmedetomidine in patients undergoing the liberation procedure. Aims: To assess the effectiveness of dexmedetomidine in providing adequate sedation and pain relief for patients undergoing the liberation procedure. Settings and design: A prospective, nonrandomized observational study of 60 consecutive adult patients undergoing the liberation procedure under monitored anesthesia care (MAC) who will receive dexmedetomidine as an anesthetic agent. Methods: A total of 60 adult patients were enrolled in the study. Dexmedetomidine was administered to all patients in a loading dose of 1 mcg/kg, which was followed by a maintenance dose of 0.2–0.5 mcg/kg/h. The evaluation of quality of sedation was based on Ramsay Sedation and the quality of analgesia was assessed using the visual analog scale. The following parameters were measured continuously: heart rate, mean arterial pressure and hemoglobin oxygen saturation. Patients were asked to answer the question, “How would you rate your experience with the sedation you have received during surgery?” using a seven-point Likert-like verbal rating scale. Statistical analysis: Repeated measurements were analyzed by repeated measures ANOVA for HR and BP. Results: Most of our patients were satisfied with their sedation. In most of the patients, MAP and HR dropped after the bolus dose of dexmedetomidine, and the drop was statistically significant. Conclusions: Dexmedetomidine can be used as a sole sedative agent in patients undergoing the liberation procedure.
机译:背景:据推测,多发性硬化症(MS)源于从大脑排出血液的静脉狭窄,医学上称为慢性脑脊髓静脉功能不全或CCSVI。已经提出,球囊血管成形术应减轻MS的症状。此过程也称为“解放过程”。因此,进行了一项临床研究,以确定右美托咪定在接受解放手术的患者中的作用。目的:评估右美托咪定在为接受解放手术的患者提供足够的镇静作用和缓解疼痛方面的效果。设置和设计:前瞻性,非随机观察性研究,对60名连续成人患者进行监测,该患者在监测麻醉护理(MAC)下接受右美托咪定作为麻醉剂。方法:共有60名成年患者参加了研究。右美托咪定以1 mcg / kg的负荷剂量施用于所有患者,随后维持剂量为0.2–0.5 mcg / kg / h。镇静质量的评估基于Ramsay镇静,镇痛质量使用视觉模拟量表进行评估。连续测量以下参数:心率,平均动脉压和血红蛋白氧饱和度。要求患者回答以下问题:“您如何评价自己在手术期间接受的镇静体验?”使用类似于李克特的7点语言评分表。统计分析:重复测量通过HR和BP的重复测量ANOVA分析。结果:我们的大多数患者对镇静感到满意。在大多数患者中,右美托咪定推注剂量后MAP和HR下降,且下降具有统计学意义。结论:右美托咪定可作为解放手术患者的唯一镇静剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号